News and Announcements
Bioactive Laboratories Closing their Fundraising Round Early
- Published August 06, 2014 5:02PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Bioactive Laboratories, a developer of a world first anti-inflammatory & pain relieving agent that is gentle to the stomach, closes their current fund raising campaign early.
Rick Ferdinands MD describes this fund raising experience: “Bioactive are grateful to the Wholesale Investor team; it’s the most effective platform to meet qualified investors in Australia. We are now able to close this fund raising campaign early and get on with business”.
As there are a number of investors who weren’t aware of the closure, Bioactive Laboratories have extended the deadline to Friday, 22nd August 2014.
As you can imagine with the strong response to the campaign, the company have already commenced the next stages of their strategic plan featuring the TGA registration completion, production trials and further customer engagement.
For those who could not make it to the Melbourne Showcase in July, you can view Rick’s presentation at www.bioactivelab.com.au/news/
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
